ABI-007 in the treatment of unresectable or recurrent gastric cancer refractory to fluoropyrimidine-containing regimen: Updated data from the multicenter phase II study.

被引：2
|
作者：
Takiuchi, Hiroya
Sasaki, Yasutsuna
Nishina, Tomohiro
Yasui, Hirofumi
Muro, Kei
Tsuji, Akihito
Koizumi, Wasaburo
Toh, Yasushi
Hara, Takuo
Miyata, Yoshinori
机构：
[1] Osaka Med Coll, Osaka, Japan
[2] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[3] Natl Hosp Org, Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[4] Shizuoka Canc Ctr, Shizuoka, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Kochi Hlth Sci Ctr, Kochi, Japan
[7] Kitasato Univ, Sagamihara, Kanagawa, Japan
[8] Natl Kyusyu Canc Ctr, Fukuoka, Japan
[9] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[10] Saku Cent Hosp, Nagano, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.90
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
90
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study
    Siena, S.
    Crino, L.
    Danova, M.
    Del Prete, S.
    Cascinu, S.
    Salvagni, S.
    Schiavetto, I.
    Vitali, M.
    Bajetta, E.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 655 - 661
  • [32] HERBIS-1: A phase II study of tri-weekly S-1 and CDDP with trastuzumab regimen in HER2-positive advanced gastric cancer (updated data)
    Okuda, H.
    Sugimoto, N.
    Miwa, H.
    Murakawa, Y.
    Shimokawa, T.
    Sakai, D.
    Kurokawa, Y.
    Tsujinaka, T.
    Furukawa, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S617 - S617
  • [33] Clinical development and evaluation of plasma angiogenesis factors from phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD): RAINCLOUD-TR.
    Hata, Tsuyoshi
    Sugimoto, Naotoshi
    Ohara, Nobuyoshi
    Miyo, Masaaki
    Yoshioka, Shinichi
    Kagawa, Yoshinori
    Naito, Atsushi
    Tei, Mitsuyoshi
    Tamagawa, Hiroshi
    Konishi, Ken
    Sawada, Genta
    Danno, Katsuki
    Shimokawa, Toshio
    Satoh, Taroh
    Miyoshi, Norikatsu
    Takahashi, Hidekazu
    Uemura, Mamoru
    Murata, Kohei
    Doki, Yuichiro
    Eguchi, Hidetoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 173 - 173
  • [34] A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).
    Katsuya, Hiroo
    Suyama, Koichi
    Kobayashi, Kazuma
    Izawa, Naoki
    Uenosono, Yoshikazu
    Hu, Qingjiang
    Kusumoto, Tetsuya
    Otsu, Hajime
    Orita, Hiroyuki
    Kawanaka, Hirofumi
    Shibao, Kazunori
    Koga, Satoshi
    Shimokawa, Mototsugu
    Makiyama, Akitaka
    Saeki, Hiroshi
    Oki, Eiji
    Baba, Hideo
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Whole-Brain Radiation Therapy Plus Concomitant Temozolomide for the Treatment of Brain Metastases from Breast Cancer: A Randomized Prospective Multicenter Phase II Study.
    Kirova, Y. M.
    Hajage, D.
    Gerber, S.
    Le, Scodan R.
    Pierga, J-Y
    Bourgier, C.
    Campana, F.
    Asselain, B.
    Fourguet, A.
    Levy, C.
    CANCER RESEARCH, 2011, 71
  • [36] Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
    Agus, D. B.
    Stadler, W. M.
    Shevrin, D. H.
    Hart, L.
    MacVicar, G. R.
    Hamid, O.
    Hainsworth, J. D.
    Gross, M. E.
    Wang, J.
    de Leon, L.
    MacLean, D.
    Dreicer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study.
    Glenjen, Nils
    Hammerling, Katrin
    Hatlevoll, Ingunn
    Smaland, Rune
    Hauge, Petra Weber
    Eide, Geir Egil
    Sorbye, Halfdan
    Dahl, Olav
    Frykholm, Gunilla
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [38] A phase II, open-label, multicenter, prospective study of paclitaxel plus capecitabine with subsequent capecitabine maintenance therapy as first-line treatment for metastatic or recurrent gastric cancer
    Shen, L.
    Gong, J.
    Zhang, X.
    Hu, B.
    Zhang, F.
    Zhang, J.
    Xu, N.
    Fan, Q.
    Bai, Y.
    Jiao, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [39] Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results
    Kim, Y. H.
    Sasaki, Y.
    Lee, K. H.
    Rha, S. Y.
    Park, S.
    Boku, N.
    Komatsu, Y.
    Kim, T.
    Kim, S.
    Sakata, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
    Agus, David B.
    Stadler, Walter Michael
    Shevrin, Daniel H.
    Hart, Lowell
    MacVicar, Gary R.
    Hamid, Omid
    Hainsworth, John D.
    Gross, Mitchell E.
    Wang, Jingyuan
    Webb, Iain James
    MacLean, David
    Dreicer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345